Glenmark Pharmaceuticals has announced that its subsidiary Glenmark Specialty SA in Switzerland and an affiliate of Bausch Health Companies Inc have entered into an exclusive licensing agreement for the commercialisation of Glenmark’s innovative nasal spray RYALTRIS under review by Health Canada.

Under the terms of the agreement, Glenmark will be responsible for regulatory approvals and supply of RYALTRIS ™ for the Canadian market. Bausch Health, Canada will be responsible for the commercialisation of RYALTRIS ™ in the Canadian market, following regulatory approval.

Glenmark will receive an upfront payment, launch and sales‐based milestone payments in addition to royalties and supply price from sales of RYALTRIS. 

RYALTRIS (Olopatadine Hydrochloride 665 mcg and Mometasone Furoate 25 mcg), is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age. 

Commenting on the agreement, Sanjeev Krishan, President & Business Head ‐ North America, Glenmark Pharmaceuticals, said, “We are pleased to partner with Bausch Health Canada, and recognise their strong foothold in the prescription and OTC market in Canada. This agreement will help us reach a larger patient population and extend the multiple benefits of RYALTRIS to a significant market. Glenmark continues to build a strong portfolio in respiratory medicine, and RYALTRIS marks our first true global brand launch till date.”   

“We are pleased to add Ryaltris to our allergy product portfolio and eager to make it available to Canadian patients suffering from allergies,” said Richard Lajoie, President, Bausch Health, Canada. 

In Canada, allergic rhinitis is estimated to afflict 25 per cent of the population, and can have a significant impact on sleep, work and school performance.